The immunogenicity of the ChAdOx1 nCoV-19 vaccination in participants with underlying comorbidity diseases: A prospective cohort study

• Váldodahkkit: Thachanun Porntharukchareon (Dahkki), Wipada Chartisathian (Dahkki), Manassamon Navinpipat (Dahkki), Chayanee Samdaengpan (Dahkki), Kunsuda Cheirsilpa (Dahkki), Aimwipa Lueprasitsakul (Dahkki), Supanat Worawichawong (Dahkki), Viroj Muangsillapasart (Dahkki), Pratya Pumuthaivirat (Dahkki), Bothamai Dechates (Dahkki), Supamas Sirisreetreerux (Dahkki), Taweegrit Siripongboonsitti (Dahkki), Vimonsri Rangsrisaeneepitak (Dahkki), Kerati Jirawattanapalin (Dahkki), Kriangkrai Tawinprai (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Taylor & Francis Group, 2023-08-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) increases mortality rates in older adults and those with comorbidities. Individuals with certain comorbidities may have a poor immune response and require early booster vaccines. We aimed to assess the immune response after two doses of Ch...